Astria Therapeutics Inc (NASDAQ:ATXS)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting 0.56. At the close of trading, the stock’s price was $4.04, to imply a decrease of -0.49% or -$0.02 in intraday trading. The ATXS share’s 52-week high remains $12.92, putting it -219.8% down since that peak but still an impressive 11.88% since price per share fell to its 52-week low of $3.56. The company has a valuation of $227.99M, with an average of 0.46 million shares in intraday trading volume over the past 10 days and average of 302.05K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Astria Therapeutics Inc (ATXS), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give ATXS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.48.
Astria Therapeutics Inc (NASDAQ:ATXS) trade information
After registering a -0.49% downside in the last session, Astria Therapeutics Inc (ATXS) has traded red over the past five days. The 5-day price performance for the stock is -13.21%, and -39.16% over 30 days. With these gigs, the year-to-date price performance is -54.81%. Short interest in Astria Therapeutics Inc (NASDAQ:ATXS) saw shorts transact 3.19 million shares and set a 13.12 days time to cover.
The extremes give us $20 and $25 for target low and target high price respectively. As such, ATXS has been trading -518.81% off suggested target high and -395.05% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 34.65% for the past 5-year period. While 2025 is set for a -14.58% return in earnings, projections for the next 5 years are at -8.54% annually.
ATXS Dividends
Astria Therapeutics Inc has its next earnings report out on 2025-Mar-10. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Astria Therapeutics Inc (NASDAQ:ATXS)’s Major holders
Astria Therapeutics Inc insiders hold 0.47% of total outstanding shares, with institutional holders owning 104.65% of the shares at 105.15% float percentage. In total, 104.65% institutions holds shares in the company, led by PERCEPTIVE ADVISORS LLC. As of 2024-06-30, the company held over 6.49 million shares (or 11.4815% of shares), all amounting to roughly $59.02 million.
The next major institution holding the largest number of shares is FMR LLC with 6.05 million shares, or about 10.7187% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $55.1 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Astria Therapeutics Inc (ATXS) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.56 shares. This is just over 2.77% of the total shares, with a market valuation of $6.31 million. Data from the same date shows that the other fund manager holds a little less at 1.35, or 2.40% of the shares, all valued at about 5.47 million.
